颈动脉产品介绍 - 支架-in service

1BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyCarotidWALLSTENTTM颈动脉支架2BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternally®支架•自膨支架•Elgiloy®金属丝•编制管状网眼结构2支架输送系统–Monorail™导管设计，0.014“导丝输送系统；–5F(6&8mm)和6F(10mm)低外廓，高柔顺性；CarotidWALLSTENTTM颈动脉支架3BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternally•闭环设计•跟踪性极佳的SDS-支架输送系统•卓越的显影性•独特的可回收能力*•唯一经FDA批准可用于双侧治疗颈动脉支架**•临床数据支持*Pleasenotethatreconstrainmentandrepositioningaresubjecttospecificlimitations.PleaserefertoDFUcautionsandwarningsforadditionalinformation.**TheCarotidWALLSTENTEndoprosthesisisindicatedforuseineligiblepatientswithipsilateralorbilateralcarotidarterydiseaseCarotidWALLSTENTTM颈动脉支架4BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternally闭环单元结构，独特的支架设计提供•最大化的斑块覆盖•高度的柔顺性•便于使用的输送系统*FreeCellArea:Measurestheaveragearea(mm2)withintheperimeterofconnectingstruts.Smallernumber=smallerfreecellarea.CarotidWALLSTENTTM颈动脉支架5BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternally支架设计-闭环Vs.开环•闭环支架设计–CarotidWALLSTENT®Endoprosthesis–Xact®CarotidStent•开环支架设计–Precise®PRORxNitinolStentSystem–RXAcculink®CarotidStentCarotidWALLSTENTEndoprosthesisPrecisePRORxNitinolStentSystemRXAcculinkCarotidStentImagestakenbyandonfileatBSC.IllustrationsbyBSC.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.6BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternally闭环支架设计•CWS与其他颈动脉支架相比，具有最小的支架网孔面积**CarotidWALLSTENT®闭环设计提供最大化的斑块覆盖以及光滑平整的管腔**TestingperformedonCarotidWALLSTENTEndoprosthesis8mmx21mm,PreciseProRX8mmx40mm,RXACCULINK7-10mmx40mm,Xact7-9mmx40mm.Benchtestresultsmaynotnecessarilybeindicativeofclinicalperformance.Testresultsshownareformodelsdeemedmosttypicallyselectedforplacementincommoncarotidarterywithareferencediameterof8mm.Othermodelswerealsotestedandyieldedsimilarresults.N=3.Dataonfile.PreciseProisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.*FreeCellArea:测量支架连接小杆周长间的平均面积数值越小=支架网孔面积越小7BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyPhotographstakenbyBostonScientificCorporation闭环支架设计CarotidWALLSTENT®闭环设计提供最大化的斑块覆盖以及光滑平整的管腔8BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyDoesCarotidStentDesignInfluenceOutcomes?R.M.Bersin,CatheterizationandCardiovascularInterventions2008;72:863–866目前为止，已经完成3项有关颈动脉支架设计与临床结果的回顾性、非随机研究。1.DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.Aretrospectiveanalysisof30dayoutcomesofacarotidarterystentingmulticenterdatabaseconsistingof3179consecutivepatients2.SPACE,aretrospective,randomizedtrialofcarotidarterystentingversusendarterectomyinstandardsurgicalriskpatientswithsymptomaticcarotidarterystenoses3.SchillingerM,GschwendtnerM,ReimersB,etal.Doescarotidstentcelldesignmatter?Aretrospective,nonrandomizedreviewofacarotidarterystentingmulticenterdatabaseconsistingof1,684consecutivepatientsDoesCarotidStentDesignInfluenceOutcomes?Bersin.CatheterizationandCardiovascularInterventions2008;72:863–866..9BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyDoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.•目的:明确颈动脉支架设计，尤其是支架网孔面积，对于颈动脉支架术后30天卒中、死亡或TIA的影响。•30天结果的回顾性分析–TIA，死亡,大和小卒中(非心肌梗死)•共3179接受颈动脉支架手术的患者•4个中心–Bosiers,Deloose-Belgium–Peeters,Verbis-Belgium–Setacci,Donatoetal.-Italy–Cremonesi,Castriota-ItalyDoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.10BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyDoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.•闭环支架定义为支架网孔面积5.0mm2–例如•CarotidWALLSTENT®Endoprosthesis•XACT®CarotidStent•开环支架定义为支架网孔面积5.0mm2–例如–Precise®RxNitinolStentSystem–RXAcculink®CarotidStentDoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.PreciseisatrademarkofCordisCorporation,AcculinkisatrademarkofAbbottCardiovascularSystems,Inc,andXactistrademarkofMedNova,Ltd.11BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternally第30天事件：闭环vs.开环支架设计TIA,死亡,大和小卒中2.3%2.3%2.2%4.2%2.2%7.0%0%1%2%3%4%5%6%7%SymptomaticAsymptomaticTotalPopulationClosedCell(5mm2)OpenCell(5mm2)DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.对于症状性患者，术后第30天的主要事件发生率差异显著开环支架设计(7.0%)VS闭环支架设计(2.2%)(p0.0001)DoesFreeCellAreaInfluencetheOutcomeinCarotidArteryStenting?Bosiersetal.EurJVascEndovascSurg2007;33:135-141.N=3179P=0.005N=1317P0.0001N=1862P=1.012BostonScientificConfidential--ForInternalUseOnly.DoNotCopy,DisplayorDistributeExternallyDoesFreeCellAreaInfluencetheOutcomei